Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, Neuland Laboratories has informed that it enclosed the schedule of Q4 and full year FY 2023 Earnings Call details.
The above information is a part of company’s filings submitted to BSE.